This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Philip Morris (PM) Up 4.6% Since Last Earnings Report?
by Zacks Equity Research
Philip Morris (PM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Philip Morris (PM) Fuels Smoke-Free Offerings With IQOS ILUMA
by Zacks Equity Research
Philip Morris International (PM) unveils the launch of IQOS ILUMA. These bladeless devices generate no smoke and combustion, and will strengthen the company's smoke-free portfolio.
Philip Morris (PM) Boosts Beyond Nicotine Options With OtiTopic
by Zacks Equity Research
Philip Morris (PM) acquires OtiTopic to expand offerings in the inhaled therapeutics and respiratory drug delivery platform. The move is part of the company's Beyond Nicotine strategy.
How Has Philip Morris' Q2 Earnings Beat Impacted Staples ETFs?
by Sweta Jaiswal, FRM
Here we highlight some consumer staples ETFs with significant exposure to Philip Morris (PM) since its earnings release.
Philip Morris (PM) Q2 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Philip Morris' (PM) second-quarter performance reflects gains from growth in revenues from combustible and RRPs categories as well as favorable pricing variance in several markets.
Philip Morris (PM) Tops Q2 Earnings Estimates
by Zacks Equity Research
Philip Morris (PM) delivered earnings and revenue surprises of 1.95% and -3.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Philip Morris (PM) This Earnings Season?
by Zacks Equity Research
Philip Morris (PM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Things Worth Noting Before Philip Morris' (PM) Q2 Earnings
by Zacks Equity Research
Philip Morris' (PM) second-quarter 2021 results are likely to reflect solid pricing power and strength in reduced risk products. However, duty-free business is likely to show weakness.
Philip Morris (PM) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Philip Morris (PM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Altria (MO) to Divest Ste. Michelle Wine Estates Business
by Zacks Equity Research
Altria's (MO) subsidiary agrees to sell Ste. Michelle Wine Estates business. The move will boost shareholders' value, while aiding in smooth transition of adult smokers to a non-combustible future.
Company News for Jul 12, 2021
by Zacks Equity Research
Companies In The News Are: LEVI, PM, UAL, MO
Why Philip Morris (PM) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Philip Morris (PM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Altria (MO) Up 14% in 6 Months, Gains on Low-Risk Products
by Zacks Equity Research
Altria's (MO) low-risk tobacco offerings such as IQOS and on! are gaining popularity. Moreover, strong pricing for tobacco products is an upside.
Things Worth Noting Before Helen of Troy's (HELE) Q1 Earnings
by Zacks Equity Research
Helen of Troy's (HELE) first-quarter fiscal 2022 results are likely to reflect strength in Leadership Brands and online sales, though elevated costs might be a worry.
Philip Morris (PM) to Boost Smoke-Free Options With Fertin Pharma
by Zacks Equity Research
Philip Morris (PM) is expected to complete the acquisition of Fertin Pharma by fourth-quarter fiscal 2021. The move is likely to help its innovation capabilities in the oral delivery platform.
The Zacks Analyst Blog Highlights: Pfizer, Qualcomm, Philip Morris International, Freeport-McMoRan and FedEx
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Qualcomm, Philip Morris International, Freeport-McMoRan and FedEx
Top Stock Reports for Pfizer, Qualcomm & Philip Morris
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), QUALCOMM (QCOM), and Philip Morris International (PM).
Philip Morris (PM) Up 10% in 3 Months, Gains on Pricing & RRPs
by Zacks Equity Research
Philip Morris (PM) is gaining from rising popularity of IQOS devices. Additionally, pricing power, especially for combustible products, is an upside.
Factors Setting the Stage for General Mills' (GIS) Q4 Earnings
by Zacks Equity Research
General Mills' (GIS) fourth-quarter fiscal 2021 results are likely to see tough comparisons with the year-ago period's stockpiling and high input costs. However, focus on core strategies bodes well.
Factors to Note Before Constellation Brands (STZ) Q1 Earnings
by Zacks Equity Research
Constellation Brands' (STZ) Q1 results are expected to reflect gains from strength in the beer business and Power Brands' growth. Higher costs and Canopy investments are likely to have been headwinds.
Philip Morris (PM) Focuses on Transformation, Shifts Headquarters
by Zacks Equity Research
Philip Morris (PM) unveils shifting of its corporate headquarters to Connecticut, which is likely to speed up its transformation toward a smoke-free future.
How Investors Can Grab Better Returns for Consumer Staples Using the Zacks ESP Screener
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Altria (MO) Gains on Low-Risk Tobacco Offerings, Strong Pricing
by Zacks Equity Research
Altria's (MO) low-risk and oral tobacco offerings are gaining popularity. Moreover, high pricing for tobacco products is an upside.
Zacks Industry Outlook Highlights: Vector Group, Philip Morris International and Altria Group
by Zacks Equity Research
Zacks Industry Outlook Highlights: Vector Group, Philip Morris International and Altria Group
Philip Morris (PM) Rewards Shareholders, Unveils New Buyback Plan
by Zacks Equity Research
Philip Morris (PM) approves a new share buyback plan of up to $7 billion and announces a quarterly dividend. Solid pricing power and strength in RRPs are key growth drivers for the company.